|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Modeling the long-term effect of PCBs on everglades fish communities 显示文摘 | Hussam A R A Koh H L DeAngelis D | 2005 | Wetlands Ecology and Management2005，13，： | 1 |
| 2 | High efficiency polycrystalline silicon solar cells using low temperature PECVD process 显示文摘 | Hussam E A Elgamel | 1998 | IEEE Transactions on Electron Devices1998，45，10： | 1 |
| 3 | Electrochemical investigation of microemulsions显示文摘 | Chokshi K Qutubuddin S Hussam A | 1989 | J Colloid Interface Sci1989，129，： | 1 |
| 4 | S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma显示文摘 | Uddin S Hussam A Ahmed M | 2008 | J Pathol2008，216，4： | 1 |
| 5 | Production of global land cover data-GLCNMO显示文摘 | Tateishi R Uriyangqai B Hussam A eta! | 2010 | International Journal of Digital Earth2010，，： | 1 |
| 6 | Tri-modal halfbridgeconverter topology for three-port interface显示文摘 | Hussam A Tian Feng Batarseh I | 2007 | IEEE Transactions on Power Electronics2007，22，1： | 1 |
| 7 | Digestive system involvement and clinical outcomes among COVID-19 patients:A retrospective cohort study from Qatar显示文摘BACKGROUND Coronavirus disease 2019(COVID-19)caused by the severe acute respiratory syndrome coronavirus 2 virus most commonly presents with respiratory symptoms.While gastrointestinal(GI)manifestations either at presentation or during hospitalization are also common,their impact on clinical outcomes is controversial.Some studies have described worse outcomes in COVID-19 patients with GI symptoms,while others have shown either no association or a protective effect.There is a need for consistent standards to describe GI symptoms in COVID-19 patients and to assess their effect on clinical outcomes,including mortality and disease severity.AIM To investigate the prevalence of GI symptoms in hospitalized COVID-19 patients and their correlation with disease severity and clinical outcomes.METHODS We retrospectively reviewed 601 consecutive adult COVID-19 patients requiring hospitalization between May 1-15,2020.GI symptoms were recorded at admission and during hospitalization.Demographic,clinical,laboratory,and treatment data were retrieved.Clinical outcomes included all-cause mortality,disease severity at presentation,need for intensive care unit(ICU)admission,development of acute respiratory distress syndrome,and need for mechanical ventilation.Multivariate logistic regression model was used to identify independent predictors of the adverse outcomes.RESULTS The prevalence of any GI symptom at admission was 27.1%and during hospitalization was 19.8%.The most common symptoms were nausea(98 patients),diarrhea(76 patients),vomiting(73 patients),and epigastric pain or discomfort(69 patients).There was no difference in the mortality between the two groups(6.21%vs 5.5%,P=0.7).Patients with GI symptoms were more likely to have severe disease at presentation(33.13%vs 22.5%,P<0.001)and prolonged hospital stay(15 d vs 14 d,P=0.04).There was no difference in other clinical outcomes,including ICU admission,development of acute respiratory distress syndrome,or need for mechanical ventilation.Drugs associated with the development of GI symptoms during hospitalization were ribavirin(diarrhea 26.37%P<0.001,anorexia 17.58%,P=0.02),hydroxychloroquine(vomiting 28.52%,P=0.009)and lopinavir/ritonavir(nausea 32.65%P=0.049,vomiting 31.47%P=0.004,and epigastric pain 12.65%P=0.048).In the multivariate regression analysis,age>65 years was associated with increased mortality risk[odds ratio(OR)7.53,confidence interval(CI):3.09-18.29,P<0.001],ICU admission(OR:1.79,CI:1.13-2.83,P=0.012),and need for mechanical ventilation(OR:1.89,CI:1.94-2.99,P=0.007).Hypertension was an independent risk factor for ICU admission(OR:1.82,CI:1.17-2.84,P=0.008)and need for mechanical ventilation(OR:1.66,CI:1.05-2.62,P=0.028).CONCLUSION Patients with GI symptoms are more likely to have severe disease at presentation;however,mortality and disease progression is not different between the two groups. | Muhammad Umair Khan Kamran Mushtaq Deema Hussam Alsoub Phool Iqbal Fateen Ata Hammad Shabir Chaudhry Fatima Iqbal Girisha Balaraju Muna A Al Maslamani Betsy Varughese Rajvir Singh Khalid Al Ejji Saad Al Kaabi Yasser Medhat Kamel Adeel Ajwad Butt | 2021 | World Journal of Gastroenterology2021，27，46： | 1 |
| 8 | Solid phase microextraction : Measurement of volatile organic com pounds ( VOCs )in Dhaka city air pollution 显示文摘 | Hussam A Alauddin M Khan A H | 2002 | Journal of Environmental Science and Health Part A- Toxic/Hazardous Substances and Environmental Engineering2002，37，7： | 1 |
| 9 | Rapid and precise method for the measurement of vapor-liquid equilibrium by headspace gas chromatography显示文摘 | Hussam A Carr P W | 1985 | Anal Chem1985，57，4： | 1 |
| 10 | The reduction phase in NOx storage catalysis:Effect of type of precious metal and reducing agent显示文摘 | HUSSAM A ERIK F MAGNUS S | 2006 | Applied Catalysis B:Environmental2006，69，3： | 1 |
| 11 | High efficiency Polycrystalline Silicon Solar Cells Using Low Temperature PECVD Process 显示文摘 | Hussam Eldin Elgamel A | 1998 | IEEE transactions on electron devices1998，45，： | 1 |
| 12 | Variation of 16S-23S internally transcribed spacer sequence and intervening sequence in rDNA among the three major Agrobacterium species显示文摘 | Jney Bautista Z Hussam H A Katsuyuki T | 2009 | Microbiological Research2009，164，： | 1 |
| 13 | Quality of life and psy-chological well-being of colorectal cancer sur- vivors in Jordan显示文摘 | AH manir AH Motasem A Hussam | 2014 | Asian Pac J Cancer Prev2014，15，18： | 1 |
| 14 | Maximum efficiency point tracking (MEPT) method and digital dead time control implementation显示文摘 | Jaber A Abu-Qahouq Hong Mao Hussam J Al-A-trash | 2006 | IEEE Transaction on Power Electronics2006，21，5： | 1 |
| 15 | High efficiency Polycrystalline Silicon Solar Cells Using Low Temperature PECVD Process 显示文摘 | Hussam Eldin Elgamel A | 1998 | IEEE transactions on electron devices1998，45，： | 1 |
| 16 | Influence of the type of reducing agent(H2,CO,C3H6and C3H8)on the reduction of stored NOxin a Pt/BaO/Al2O3 model catalyst显示文摘 | HUSSAM A ERIC F MAGNUS S | 2004 | Topics in Catalysis2004，3031，1234： | 1 |
| 17 | Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2Diabetes A Meta-Analysis of Randomized Clinical Trials显示文摘 | Hussam A Philip GJ Steven P | 2005 | J Am Coll Cardiol2005，46，5： | 1 |
| 18 | Multifocal chloroma appearance by PET/CT scan显示文摘 | Hussam A AI-Kaylani Arwa Y Alami | 2008 | 中国口腔颌面外科杂志2008，6，B05： | 0 |
| 19 | Effect of fibrinolytic therapy on ST-elevation myocardial infarction clinical outcomes during the COVID-19 pandemic:A systematic review and meta-analysis显示文摘BACKGROUND ST-elevation myocardial infarction(STEMI)is the result of transmural ischemia of the myocardium and is associated with a high mortality rate.Primary percutaneous coronary intervention(PPCI)is the recommended first-line treatment strategy for patients with STEMI.The timely delivery of PPCI became extremely challenging for STEMI patients during the coronavirus disease 2019(COVID-19)pandemic,leading to a projected steep rise in mortality.These delays were overcome by the shift from first-line therapy and the development of modern fibrinolytic-based reperfusion.It is unclear whether fibrinolytic-based reperfusion therapy is effective in improving STEMI endpoints.AIM To determine the incidence of fibrinolytic therapy during the COVID-19 pandemic and its effects on STEMI clinical outcomes.METHODS PubMed,Google Scholar,Scopus,Web of Science,and Cochrane Central Register of Controlled Trials were queried from January 2020 up to February 2022 to identify studies investigating the effect of fibrinolytic therapy on the prognostic outcome of STEMI patients during the pandemic.Primary outcomes were the incidence of fibrinolysis and the risk of all-cause mortality.Data were meta-analyzed using the random effects model to derive odds ratios(OR)and 95%confidence intervals.Quality assessment was carried out using the Newcastle-Ottawa scale.RESULTS Fourteen studies including 50136 STEMI patients(n=15142 in the pandemic arm;n=34994 in the pre-pandemic arm)were included.The mean age was 61 years;79%were male,27%had type 2 diabetes,and 47%were smokers.Compared with the pre-pandemic period,there was a significantly increased overall incidence of fibrinolysis during the pandemic period[OR:1.80(1.18 to 2.75);I2=78%;P=0.00;GRADE:Very low].The incidence of fibrinolysis was not associated with the risk of all-cause mortality in any setting.The countries with a low-and middle-income status reported a higher incidence of fibrinolysis[OR:5.16(2.18 to 12.22);I2=81%;P=0.00;GRADE:Very low]and an increased risk of all-cause mortality in STEMI patients[OR:1.16(1.03 to 1.30);I2=0%;P=0.01;GRADE:Very low].Meta-regression analysis showed a positive correlation of hyperlipidemia(P=0.001)and hypertension(P<0.001)with all-cause mortality.CONCLUSION There is an increased incidence of fibrinolysis during the pandemic period,but it has no effect on the risk of all-cause mortality.The low-and middle-income status has a significant impact on the all-cause mortality rate and the incidence of fibrinolysis. | Anwar Khedr Hussam Al Hennawi Muhammed Khuzzaim Khan Mostafa Elbanna Abbas B Jama Ekaterina Proskuriakova Hisham Mushtaq Mikael Mir Sydney Boike Ibtisam Rauf Aalaa Eissa Meritxell Urtecho Thoyaja Koritala Nitesh Jain Lokesh Goyal Salim Surani Syed A Khan | 2023 | World Journal of Cardiology2023，15，6： | 0 |
| 20 | Cranial neuropathies in sarcoidosis显示文摘Sarcoidosis is a multisystem, chronic inflammatory disease that is characterized by the development of non-caseating granulomas in multiple body tissues and organ systems. Neurological complications of systemic sarcoidosis include peripheral and cranial neuropathies, myopathies, seizures, gait dysfunction, and cognitive decline. Because sarcoidosis has a predilection to involve the basilar meninges, cranial neuropathy is the most prevalent neurological deficit seen when the nervous system is involved. Sarcoidosis cranial neuropathy may occur at different stages of the disease and even as the initial clinical manifestation of central nervous system involvement. Attributing a cranial neuropathy to sarcoidosis can be challenging, particularly in the setting of normal imaging studies. In this review, cranial neuropathies in sarcoidosis are discussed in detail. | Hussam A Yacoub Zaid A Al-Qudah Nizar Souayah | 2015 | World Journal of Ophthalmology2015，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员